Figure 7
From: Spatiotemporal analysis of soluble aggregates and autophagy markers in the R6/2 mouse model
Nilotinib (Tasigna™) is ineffective in enhancing the clearance of mHTT aggregates at any given stage of disease progression in R6/2. (A)–(D) Representative immunoblot showing no effect of Tasigna in clearing mHTT aggregates (EM48) from 6, 8, 10, and 12 weeks in the cortex, Hippocampus, striatum and cerebellum, respectively. (E)–(H) Pooled quantified bar graphs for mHTT aggregates for cortex: Age x treatment (F(3,12) = 0.26, p = 0.84), hippocampus: Age x treatment (F(3,12) = 0.49, p = 0.69), striatum: Age x treatment (F(3,12) = 1.27, p = 0.32) , and cerebellum Age x treatment (F(3,12) = 4.603, p = 0.02). N = 3 (R6/2-Saline), and (R6/2-Tasigna) for all the 4 age groups 6, 8, 10, and 12 weeks. Error bars indicate ± SEM. (Mean and ± SEM values are represented in supplementary Table 6). N = number of mice. The treatment groups are separated by vertical dashed lines. Statistical analysis was done by Two-way ANOVA followed by Bonferroni post-hoc test. Image brightness and contrast were adjusted for representative purpose. Blots with different exposures and full uncropped raw blots are represented in the supplementary Figs. S4 and S12, respectively.
